Health insurance companies are lobbying the Trump administration to reject Biden-era proposals that would expand Medicare and Medicaid prescription access to weight-loss medications such as Wegovy and Ozempic.

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans, and reducing prices for certain dosages.